Find a Doctor
Find a Location
View All Services
Request Records
Pay a Bill
Check Symptoms
Video Visits
Urgent Care
Clinical Trials
Research Studies
Publications
Investigators
Vincent A. Gaudiani, MD, practices thoracic surgery at Palo Alto Medical Foundation in Redwood City and San Francisco, California. He and his surgical team began performing open heart surgery in San Francisco in 2007. They have implemented their system of care evolved since 1988, focused on quality assurance and a committed team effort.
Sutter Health Research Enterprise
2900 Whipple Avenue
Suite 225
Redwood City, CA, 94062
(650) 366-0225
gaudiav@sutterhealth.org
Primary Research Interests
Related Clinical Trials
CoreValve Pivotal Trial
Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk Subjects Who Need Aortic Valve Replacement
Investigators: Vincent A. Gaudiani M.D., Physician, Thoracic Surgery, Chad Rammohan M.D., FACC
Status: Active, Recruiting
CoreValve SURTAVI
Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)
Investigators: Vincent A. Gaudiani M.D., Physician, Thoracic Surgery, Chad Rammohan M.D., FACC
Status: Active, Recruiting
SURTAVI
Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)
Investigator: Vincent A. Gaudiani M.D., Physician, Thoracic Surgery
Status: Active, Not Recruiting
Publications
Mitral valve operations through standard and smaller incisions.
Mortality rate for MV operations is concentrated among a few diagnoses. In some patients, surgery may be approached safely through smaller incisions.
Process improvement: the sorcerer and the sorcerer's apprentice.
In this essay, I focus on how we should think about emerging "guidelines" that standardize care for hospitalized patients who require cardiac operations.
Should the financial link between industry and physician consultants be severed?
This debate focuses on the question of whether the financial connections that link physicians and industry should be broken. The two experts in this debate agree that change is coming in the form of increased scrutiny and regulation, but they have differing views of where regulatory policy is or should be headed.
Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial.
Among patients with severe aortic stenosis, TAVR with a self-expanding bioprosthesis resulted in substantial improvements in both disease-specific and generic health-related quality of life, but there remained a large minority of patients who died or had very poor quality of life despite TAVR.